Amicus Therapeutics Inc.Find Ratings Reports
AMICUS THERAPEUTICS INC's gross profit margin for the third quarter of its fiscal year 2017 has significantly increased when compared to the same period a year ago. Even though sales increased, the net income has decreased, representing a decrease to the bottom line. AMICUS THERAPEUTICS INC is extremely liquid. Currently, the Quick Ratio is 6.13 which clearly shows the ability to cover any short-term cash needs. The company's liquidity has increased from the same period last year.
During the same period, stockholders' equity ("net worth") has increased by 21.72% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is very unlikely to face financial difficulties in the near future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
|Income Statement||Q3 FY17||Q3 FY16|
|Net Sales ($mil)||10.87||2.13|
|Net Income ($mil)||-111.67||-46.65|
|Balance Sheet||Q3 FY17||Q3 FY16|
|Cash & Equiv. ($mil)||411.52||212.4|
|Total Assets ($mil)||680.78||918.18|
|Total Debt ($mil)||161.64||66.02|
|Profitability||Q3 FY17||Q3 FY16|
|Gross Profit Margin||-133.24||-797.98|
|Return on Assets||-40.16||-20.07|
|Return on Equity||-66.74||-54.75|
|Debt||Q3 FY17||Q3 FY16|
|Share Data||Q3 FY17||Q3 FY16|
|Shares outstanding (mil)||165.49||142.27|
|Div / share||0.0||0.0|
|Book value / share||2.48||2.37|
|Institutional Own %||n/a||n/a|
|Avg Daily Volume||2555606.0||3276088.0|
SELL. The current P/E ratio is negative, which has no meaningful value in the assessment of premium or discount valuation, it simply displays that the company has negative earnings. To use another comparison, its price-to-book ratio of 6.39 indicates a significant premium versus the S&P 500 average of 3.26 and a significant discount versus the industry average of 15.63. The price-to-sales ratio is well above both the S&P 500 average and the industry average, indicating a premium. The valuation analysis reveals that, AMICUS THERAPEUTICS INC seems to be trading at a premium to investment alternatives within the industry.
|FOLD NM||Peers 46.82||FOLD NM||Peers 41.91|
Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.
FOLD's P/E is negative making this valuation measure meaningless.
Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.
FOLD's P/CF is negative making the measure meaningless.
|FOLD NM||Peers 28.60||FOLD NA||Peers 0.35|
Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings.
FOLD's ratio is negative making this valuation measure meaningless.
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.
Ratio not available.
|FOLD 6.39||Peers 15.63||FOLD -28.87||Peers 2.21|
Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.
FOLD is trading at a significant discount to its peers.
Lower. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.
However, FOLD is expected to significantly trail its peers on the basis of its earnings growth rate.
|FOLD 104.66||Peers 87.22||FOLD 1076.86||Peers 120.94|
Premium. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.
FOLD is trading at a premium to its industry on this measurement.
Higher. A sales growth rate that exceeds the industry implies that a company is gaining market share.
FOLD has a sales growth rate that significantly exceeds its peers.